Start a live chat
1-800-870-4800
What happens to NAD+
as the body ages —
and why it matters.
NAD+ does not decline because the body forgets how to make it. It declines because a precise sequence of biological changes — unfolding over decades, invisible from the outside — gradually overwhelms the cellular systems designed to keep it replenished. Understanding that sequence is one of the more important things anyone seriously interested in longevity can do.
I
The quiet decline —
how a molecule central to life begins to fall short.
There is no single moment when NAD+ begins to decline. No threshold crossed, no signal sent. It happens the way most consequential biological changes happen — gradually, distributed across years, driven by mechanisms so fundamental that the body itself does not register them as a departure from normal. By the time the downstream effects of NAD+ insufficiency become apparent in how a person feels, the decline has been underway for decades.
NAD+ — nicotinamide adenine dinucleotide — is present in every cell of the body and required for processes ranging from the basic chemistry of energy production to the sophisticated maintenance systems cells use to repair damage and regulate gene expression. In youth, the body maintains NAD+ levels with relative ease. The Salvage Pathway — the biochemical recycling system responsible for producing the majority of NAD+ in adult tissue — runs efficiently. The enzymes that consume NAD+ draw on a pool that is continuously and adequately replenished. The cellular economy is balanced.
That balance begins to shift, by degrees, through the middle decades of life. Not because the body stops caring about NAD+. Because several distinct biological changes — each independently significant, collectively compounding — begin to erode both the production side and the replenishment side of the NAD+ equation simultaneously. The result, across the arc of a human lifetime, is one of the most consistent and consequential molecular changes that aging biology has documented.
NAD+ does not disappear.
It is outspent —
production falling, demand rising,
the gap widening across decades.
The Arc of a Lifetime
How the NAD+ story changes
across the decades of a human life.
This is not a timeline of disease. It is a timeline of biology — the normal, universal arc of how the NAD+ system evolves across a lifespan in the absence of any intervention.
The NAD+ system at its most capable
In early adulthood, NAD+ levels are at or near their lifetime peak. NAMPT — the enzyme that drives the Salvage Pathway — functions with high efficiency. The body's DNA repair systems, mitochondrial networks, and cellular maintenance machinery draw on an NAD+ pool that is reliably replenished. The energy metabolism cycle runs cleanly. Sirtuins — the NAD+-dependent proteins that regulate gene expression and coordinate cellular stress responses — have the substrate they need to function at full capacity. This is the biological baseline that everything that follows departs from.
The first measurable changes in NAD+ availability
The third decade of life is when measurable declines in NAD+ availability begin to appear in tissue studies — subtle enough that they produce no obvious symptoms, significant enough that they register as a consistent pattern across the biological data. NAMPT activity begins its gradual downward trend. The accumulated DNA damage that drives PARP activation starts to accumulate faster than the repair mechanisms can fully clear it, beginning a cycle where DNA damage consumes more NAD+ than the young-adult system had budgeted for. The NAD+ economy begins, almost imperceptibly, to run a deficit.
Declining production meets rising demand
The fourth decade is where the compounding nature of NAD+ decline becomes biologically meaningful. NAMPT activity has declined enough to measurably reduce the throughput of the Salvage Pathway. CD38 — the enzyme that degrades NAD+ as part of immune and calcium signaling — begins to increase in expression as the body's low-grade inflammatory baseline rises with age. The mitochondrial networks, which depend on adequate NAD+ for the electron transport chain that produces cellular energy, begin to show the first signs of functional decline. The pool is being drawn down on two fronts simultaneously: less is being produced, and more is being consumed and degraded.
NAD+ insufficiency becomes systemic across tissues
By the fifth and sixth decades, NAD+ levels in many tissues are estimated to have fallen to roughly half of their youthful peak. The consequences are no longer confined to molecular bookkeeping. Mitochondrial dysfunction — partly a downstream effect of NAD+ decline — is now measurable in muscle tissue, heart tissue, and the brain. Sirtuin activity, constrained by insufficient NAD+, is less able to maintain the epigenetic and metabolic regulation that keeps cells functioning as their younger counterparts did. The DNA repair response, dependent on PARP enzymes that consume NAD+ with each activation, is slower and less complete. The cellular maintenance systems are operating on a reduced budget.
The deepest phase of NAD+ decline across the body's systems
In the seventh decade and beyond, NAD+ decline is profound and broadly systemic. The Salvage Pathway's throughput — already reduced by decades of declining NAMPT activity — is now operating alongside an increasingly inflamed cellular environment where CD38 expression is substantially elevated and NAD+ degradation is significantly faster than it was in youth. The body's capacity for cellular repair, metabolic efficiency, mitochondrial biogenesis, and stress response is operating at a fraction of its youthful capacity — not because those systems have failed, but because the molecular currency they require to function has been systematically depleted by the accumulated biology of aging.
II
Three forces driving the decline —
and why they compound each other.
NAD+ decline is not a single-cause phenomenon. It is the product of at least three distinct biological dynamics that operate simultaneously — each significant on its own, and each made worse by the presence of the others.
The first is the decline in production. NAMPT, the enzyme at the heart of the Salvage Pathway, loses activity with age in a pattern that appears across multiple tissue types. Because NAMPT governs the rate-limiting step in the body's primary NAD+ recycling system, its decline reduces the throughput of the entire pathway. Less nicotinamide gets converted to NMN. Less NMN gets converted to NAD+. The pool shrinks from the supply side.
The second is the rise in degradation. CD38, an enzyme whose expression is associated with the inflammatory environment that deepens with age, degrades NAD+ at an accelerating rate. In young tissue, CD38 activity is relatively contained. As the body's background inflammatory state increases — a phenomenon sometimes described as inflammaging — CD38 expression rises, and the rate at which NAD+ is broken down before it can be used by sirtuins or metabolic enzymes increases with it. The pool shrinks from the demand and degradation side.
The third is the accumulation of DNA damage. Every strand break that occurs — from oxidative stress, radiation, metabolic byproducts, or the simple errors of cellular replication — activates PARP enzymes, which consume NAD+ to execute the repair response. In youth, the rate of DNA damage and the NAD+ available for repair are in rough equilibrium. With age, accumulated damage outpaces clearance, PARP activation becomes more frequent, and each activation draws on an NAD+ pool that is already depleted by the first two dynamics. The three forces form a compounding loop that aging biology has not yet found a simple way to interrupt.
The Three-Force Framework
Why NAD+ decline accelerates —
the compounding dynamics.
Force 01 · Production
NAMPT activity falls with age
The Salvage Pathway's rate-limiting enzyme declines across multiple tissue types as the body ages. Less NAMPT activity means less NMN produced from nicotinamide — and less NMN means less NAD+ synthesized. The decline in production capacity compounds across decades, narrowing the NAD+ pool from its supply side even before consumption and degradation are factored in.
Force 02 · Degradation
CD38 expression rises with inflammation
CD38 degrades NAD+ and its expression increases substantially in aged tissues alongside the rising inflammatory background that accumulates with age. While NAMPT decline reduces how much NAD+ the body can make, rising CD38 activity accelerates how fast it is broken down. The two dynamics together — less produced, more degraded — create a compounding deficit that neither force alone would generate.
Force 03 · Demand
DNA damage accumulates, driving PARP consumption
PARP enzymes consume NAD+ each time they respond to DNA damage. With age, the accumulation of DNA damage outpaces the body's capacity to clear it fully, meaning PARP enzymes are activated more frequently — and each activation draws on an NAD+ pool already stressed by declining production and rising degradation. Demand rises precisely as supply falls.
The Nature of the Decline
What makes NAD+ decline
so consequential — and so easy to miss.
The downstream effects — felt, but rarely traced to their source.
Changes in energy and physical stamina across the middle decades
Slower recovery from physical and biological stress
Changes in metabolic efficiency that accumulate gradually
Shifts in sleep architecture and circadian rhythm stability
Declining muscle mass and strength that begins earlier than most expect
The general sense of biological change that arrives through the forties
The molecular reality — unfolding at the cellular level, decades before the surface changes.
NAMPT activity declining in muscle, liver, brain, and heart tissue
CD38 expression rising alongside the body's inflammatory background
Sirtuin activity constrained by an NAD+ pool that can no longer sustain full function
Mitochondrial networks becoming less efficient as their NAD+ supply narrows
DNA repair becoming slower and less complete with each passing decade
The NAD+/NADH ratio shifting in ways that alter the cellular metabolic state
The Scale of the Decline
How far NAD+ falls —
and across how many systems.
~50%
Estimated NAD+ decline from young adulthood to midlife across tissue studies
Tissue studies examining NAD+ levels across age groups have documented declines in the range of 40–50% from young adulthood to midlife, with continued decline thereafter. This is not a marginal change. It represents a substantial reduction in the substrate that hundreds of enzymatic processes depend on — sustained across every tissue in the body simultaneously. Studies were conducted independently and did not involve any specific Codeage product.
All
Tissues in which age-related NAD+ decline has been documented
NAD+ decline is not tissue-specific. It has been documented across muscle, liver, brain, heart, adipose tissue, skin, and kidney — reflecting the universal dependency of cellular metabolism on NAD+ availability. The breadth of affected tissues is part of what makes NAD+ decline a systemic aging phenomenon rather than a localized one, and what gives the biology of NAD+ restoration its wide scope of potential relevance.
2–3×
Estimated increase in CD38 expression in aged versus young tissues
Studies on aged tissue have documented CD38 expression levels substantially higher than in young tissue — in some cases two to three times greater. This elevated CD38 activity represents a significant acceleration in NAD+ degradation that compounds the simultaneous decline in production via the Salvage Pathway, creating the double-sided deficit that characterizes the aging NAD+ system. Studies were conducted independently and did not involve any specific Codeage product.
III
Why this is the beginning
of the NMN conversation, not the end.
Understanding what happens to NAD+ as the body ages is not an endpoint. It is a foundation — the biological context without which the NMN conversation has no real meaning. The reason NMN has become one of the most studied molecules in longevity biology is precisely because of everything described here: a molecule whose decline is documented, whose mechanisms of decline are understood, and whose production pathway has a clearly identified precursor that the body can use to partially offset that decline.
NMN enters the picture as a direct Salvage Pathway substrate — bypassing the NAMPT bottleneck that is one of the primary causes of reduced NAD+ production with age, and delivering the molecule one enzymatic step away from NAD+ itself. It does not reverse the biological dynamics that drive CD38 expression higher. It does not undo accumulated DNA damage. What it does is supply the pathway at its most efficient entry point, in a cellular context where the natural supply of that pathway's substrate has been systematically reduced by decades of aging biology.
That is the honest framing of what NAD+ decline means, and where NMN fits within it. Not a correction of aging. A considered response to one of its most fundamental molecular dimensions — which is exactly the standard that Cellular Longevity, Pillar 03 of The Longevity Code, is built around. For a deeper look at the NMN–NAD+ relationship itself, the cellular relationship article covers each enzyme in the system in full.
The decline is real.
The mechanisms are understood.
The question longevity biology
is now working to answer
is what to do about them.
Codeage · Pillar 03 · Cellular Longevity
Built for the
cellular long game.
Cellular Longevity is Pillar 03 of The Longevity Code — the dimension of the system built around NAD+ biology, mitochondrial health, and the science of cellular aging.
Explore Cellular Longevity →
